ReviewNature reviews. Rheumatology2016
New evidence on the management of spondyloarthritis.
Review in Nature reviews. Rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis.Molecular medicine (Cambridge, Mass.) · 2019Trial
- Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.Arthritis research & therapy · 2016Trial
- Characteristics and multi-omics analysis of spontaneous spondyloarthritis in non-human primates: Case report.Heliyon · 2025Article
- Evaluation of remission in patients with radiographic axial spondyloarthritis using an ultrasonography-based enthesitis score: a cross-sectional study.Reumatologia · 2025Article
- Programmed cell death 10 can be used as a potential biomarker for ankylosing spondylitis diagnosis and treatment.Spinal cord · 2024Article
- Article
- Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis.International journal of molecular sciences · 2023Review
- Reiter's syndrome following intravesical Bacillus Calmette-Guerin therapy for bladder carcinoma: Case report.IDCases · 2023Article
- Transfer of microRNA-22-3p by M2 macrophage-derived extracellular vesicles facilitates the development of ankylosing spondylitis through the PER2-mediated Wnt/β-catenin axis.Cell death discovery · 2022Article
- Expert recommendations on early diagnosis and referral of axial spondyloarthritis in the Kingdom of Saudi Arabia.Clinical rheumatology · 2022Review
- The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies.Cells · 2022Review
- Machine Learning in Rheumatic Diseases.Clinical reviews in allergy & immunology · 2021Review
- Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents.Journal of experimental pharmacology · 2021Review
- Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis.Clinical rheumatology · 2021Review
- Similarities and Differences Between Juvenile and Adult Spondyloarthropathies.Frontiers in medicine · 2021Review
- Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial.Therapeutic advances in musculoskeletal disease · 2021Article
- An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study.Frontiers in medicine · 2021Article
- Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics.Open access rheumatology : research and reviews · 2021Review
- Effectiveness of Steroid Pulse Therapy for Systemic Side Effects after Bacillus Calmette-Guérin Intravesical Instillation Therapy: A Series of Five Cases.Case reports in urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for patients with symptomatic axial spondyloarthritis (SpA), who seem to respond best if treated early in the course of disease. The effect of NSAIDs on radiographic disease progression is less clear. Conventional disease-modifying antirheumatic drugs (DMARDs) are not recommended in the treatment of axial SpA, either alone or in combination with TNF blockers. Patients with nonradiographic axial SpA (nr-axSpA) seem to respond as well to TNF blockers as do patients with radiographic axial SpA (ankylosing spondylitis (AS)). However, patients with nr-axSpA should, in addition to a high severity of symptoms, also have objective signs of inflammation, detectable by MRI or by C-reactive protein testing, to be treated with TNF blockers. Whether early TNF-blocker treatment can retard new bone formation needs clarification. In clinical trials, anti-IL-17 agents and TNF blockers showed similar efficacy in patients with AS. The potential of IL-23 blockade for treatment of axial SpA needs to be further investigated. Treatment options for peripheral SpA have been much less thoroughly investigated than those for axial SpA. However, some data indicate that TNF blockers are effective for treating peripheral arthritis, enthesitis and dactylitis, the typical manifestations of peripheral SpA.
Indexed as
Identifiers
27052489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.